The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Learn about side effects, cost, and more of Dupixent (dupilumab). It’s a prescription drug that treats atopic dermatitis (a type of eczema) and other conditions.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Ben Sutter could only eat three things after being diagnosed with eosinophilic gastroenteritis as a baby. A medical ...

Dupixent is the first medication to show significant and robust impacts in this patient population,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific ...

After 6 months of treatment, people who used Dupixent were more likely to have fewer and smaller nasal polyps than the people who used a placebo. One study measured the polyps again after a year ...

A separate study looked at Dupixent in people who had a severe type of asthma, called corticosteroid-dependent asthma. This study included people who were 12 years and older, with an average age ...